Literature DB >> 8642882

Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients.

M Castro1, M J Krowka, D R Schroeder, K C Beck, D J Plevak, S R Rettke, D A Cortese, R H Wiesner.   

Abstract

OBJECTIVE: To characterize the pulmonary hemodynamics and identify predictors of pulmonary hypertension in a group of patients before liver transplantation and to determine whether pulmonary hypertension in these patients is related to survival.
MATERIAL AND METHODS: In 362 patients before their first liver transplantation (between 1985 and 1993), the clinical history, laboratory data, and results of pulmonary function tests were recorded. Pulmonary artery (PA) catheterization was performed after induction of anesthesia at the time of transplantation. Monthly follow-up was maintained.
RESULTS: A hyperdynamic circulation was often present -- an increased mean cardiac output (7.6 L/min), increased mean PA pressure (20.9 mm Hg), correlation of mean PA pressure with cardiac output (r = 0.25; P<0.001), and decreased mean pulmonary vascular resistance (60 dynes times s/cm5). Mean PA pressures were more than 25 mm Hg in 72 patients (20%). Pulmonary hypertension (defined as mean PA pressure of more than 25 mm Hg and pulmonary vascular resistance in excess of 120 dynes times s/cm5) occurred in 15 patients (4%). Pulmonary function tests revealed obstruction in 7%, restriction in 18%, and low diffusing capacity in 46%. By univariate analysis, lower forced expiratory volume in 1 second, forced vital capacity, and total lung capacity were the only preoperative factors associated with pulmonary hypertension (P<0.05). Survival was significantly lower in patients with acute fulminant hepatitis (P<0.001), the group with the highest mean PA pressure, than in those with other diagnoses. Increased PA pressures or mild to moderate pulmonary hypertension was not found to be associated with a worse survival by univariate or multivariate analysis.
CONCLUSION: Increased PA pressure is common in liver transplant patients (20%). "True" pulmonary hypertension occurred in only 4% of our patients and was not associated with an adverse outcome.

Entities:  

Mesh:

Year:  1996        PMID: 8642882     DOI: 10.4065/71.6.543

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  35 in total

1.  Hepatopulmonary syndromes.

Authors:  M J Krowka
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  Pathogenesis of pulmonary arteriovenous malformations: role of hepatopulmonary interactions.

Authors:  J J Vettukattil
Journal:  Heart       Date:  2002-12       Impact factor: 5.994

3.  Portopulmonary hypertension: challenges in diagnosis and management.

Authors:  Patrick J Troy; Aaron B Waxman
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 4.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

5.  Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension.

Authors:  Yu Yamashita; Ichizo Tsujino; Takahiro Sato; Asuka Yamada; Taku Watanabe; Hiroshi Ohira; Masaharu Nishimura
Journal:  World J Hepatol       Date:  2014-11-27

Review 6.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

Review 7.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

8.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

Review 9.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

10.  Portopulmonary hypertension in decompensated cirrhosis with refractory ascites.

Authors:  F S Benjaminov; M Prentice; K W Sniderman; S Siu; P Liu; F Wong
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.